Literature DB >> 9113369

The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes.

C E Gargett1, J S Wiley.   

Abstract

1. Extracellular adenosine 5'-triphosphate (ATP) is an agonist for a P2Z receptor on human lymphocytes which mediates opening of a cation-selective ion channel, activation of phospholipase D and shedding of the adhesion molecule, L-selectin, from the cell surface. The isoquinolinesulphonamides, KN-62, (1-[N, O-bis(5-isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4-phenylpiperaz ine), a selective antagonist of Ca2+/calmodulin-dependent protein kinase II (CaMKII), and KN-04, (N-[1-[N-methyl-p-(5 isoquinoline sulphonyl)benzyl]-2-(4 phenylpiperazine)ethyl]-5-isoquinolinesulphonamide) an inactive analogue, were used to investigate the possible role of CaMKII in these diverse effects of extracellular ATP. 2. KN-62 potently antagonized ATP-stimulated Ba2+ influx into fura-2 loaded human lymphocytes with an IC50 of 12.7 +/- 1.5 nM (n = 3) and complete inhibition of the flux at a concentration of 500 nM. Similarly, KN-62 inhibited ATP-stimulated ethidium+ uptake, measured by time resolved flow cytometry, with an IC50 of 13.1 +/- 2.6 nM (n = 4) and complete inhibition of the flux at 500 nM. 3. KN-04 antagonized ATP-stimulated Ba2+ influx with an IC50 of 17.3 +/- 2.7 nM (n = 3). Similarly, KN-04 inhibited ATP-stimulated ethidium+ uptake with an IC50 of 37.2 +/- 8.9 nM (n = 4). Both fluxes were completely inhibited at 500 nM KN-04. 4. ATP-stimulated phospholipase D activity, measured in [3H]-oleic acid-labelled lymphocytes by the transphosphatidylation reaction, was antagonized by KN-62 and KN-04, with 50% inhibition at 5.9 +/- 1.2 and 9.7 +/- 2.8 nM (n = 3), respectively. Both KN-62 and KN-04 inhibited ATP-stimulated shedding of L-selectin, measured by flow cytometric analysis of cell surface L-selectin, with IC50 values of 31.5 +/- 4.5 and 78.7 +/- 10.8 nM (n = 3), respectively. Neither of the isoquinolinesulphonamides (500 nM) inhibited phorbol ester- or ionomycin-stimulated phospholipase D activity or phorbol ester-induced shedding of L-selectin. 5. The inhibitory effect of KN-62 or KN-04 on P2Z-mediated responses was slow in onset (5 min) and only partially reversed by washing the cells. 6. Both KN-62 and KN-04 (at 500 nM) had no effect on uridine 5'-triphosphate (UTP)-stimulated Ca2+ transients in fura-2 loaded human neutrophils, a response which is mediated by the P2Y2 receptor. 7. Thus, KN-62 and KN-04 are potent antagonists of the P2Z receptor and at nanomolar concentrations inhibit all known responses mediated by the P2Z receptor of human lymphocytes. In contrast, KN-62 and KN-04 had no effect on responses mediated by the P2Y2 receptor of neutrophils. Moreover, since KN-62 and KN-04 are almost equipotent, the P2Z-mediated responses do not involve CaMKII, but indicate that the isoquinolinesulphonamides are potent and direct inhibitors of the P2Z-receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9113369      PMCID: PMC1564633          DOI: 10.1038/sj.bjp.0701081

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  P2X7 receptors in Müller glial cells from the human retina.

Authors:  T Pannicke; W Fischer; B Biedermann; H Schädlich; J Grosche; F Faude; P Wiedemann; C Allgaier; P Illes; G Burnstock; A Reichenbach
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  ATP-P2X7 receptor signaling controls basal and TNFα-stimulated glial cell proliferation.

Authors:  Jian Zou; Ryan P Vetreno; Fulton T Crews
Journal:  Glia       Date:  2012-02-01       Impact factor: 7.452

Review 3.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

Review 4.  Mechanisms for inhibition of P2 receptors signaling in neural cells.

Authors:  Fernando A González; Gary A Weisman; Laurie Erb; Cheikh I Seye; Grace Y Sun; Betty Velázquez; Melvin Hernández-Pérez; Nataliya E Chorna
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 5.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

6.  Negative and positive allosteric modulators of the P2X(7) receptor.

Authors:  A D Michel; L J Chambers; D S Walter
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

7.  Antagonist effects on human P2X(7) receptor-mediated cellular accumulation of YO-PRO-1.

Authors:  A D Michel; R Kaur; I P Chessell; P P Humphrey
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

8.  Functionalized congeners of tyrosine-based P2X(7) receptor antagonists: probing multiple sites for linking and dimerization.

Authors:  Wangzhong Chen; R Gnana Ravi; Sylvia B Kertesy; George R Dubyak; Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2002 Sep-Oct       Impact factor: 4.774

Review 9.  Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states.

Authors:  D L Donnelly-Roberts; M F Jarvis
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

10.  Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects.

Authors:  A D Michel; W C Clay; S W Ng; S Roman; K Thompson; J P Condreay; M Hall; J Holbrook; D Livermore; S Senger
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.